Matritech seeks expanded approval for cancer test:
This article was originally published in Clinica
Matritech is seeking to expand US approval for its NMP22 bladder cancer test to include initial detection of the disease. The test is currently approved by the FDA for the management of patients already diagnosed with bladder cancer, although the Japanese government has authorised reimbursement for its use in cancer screening. The Newton, Massachusetts-based company has submitted results of a clinical study involving 1,147 subjects to the FDA, which found that the test had 85% sensitivity in detecting late stage bladder cancer, in high-risk but previously undiagnosed patients. Overall sensitivity to all forms of bladder cancer was 70%.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.